Celldex Therapeutics Appoints Margo Heath-Chiozzi, M.D., as Senior Vice President, Regulatory Affairs
October 03 2017 - 8:00AM
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that Margo
Heath-Chiozzi, M.D., has joined the Company as Senior Vice
President, Regulatory Affairs. She was previously Vice President,
Global Submissions and Regulatory Policy at Bristol-Myers Squibb
Company, where she provided executive global regulatory strategy
leading to nine product approvals. Dr. Heath-Chiozzi brings over 25
years of experience in senior leadership roles in regulatory
sciences, pharmacogenetics and product development within the
pharmaceutical industry and as a practicing physician and clinical
researcher.
“Dr. Heath-Chiozzi’s strong track record of drug approvals and
her exceptional understanding of the regulatory environment
position her well to lead our global regulatory strategy,” said
Anthony Marucci, Co-founder, President and Chief Executive Officer
of Celldex Therapeutics. “She is sincerely passionate about drug
development and making a difference in the lives of patients, and
we look forward to working with her as we execute across our deep
pipeline of drug candidates.”
“I’m looking forward to working with the Celldex team to develop
commercial strategies across its deep pipeline, especially as
topline results from the METRIC study of glembatumumab vedotin in
patients with triple-negative breast cancer are anticipated within
the coming months,” said Dr. Heath-Chiozzi. “It’s an exciting time
for the organization, and I’m thrilled to be a member of the
team.”
Dr. Heath-Chiozzi joined Bristol-Myers Squibb in 2003, and prior
to her most recent role, she served as Vice President, Global
Regulatory Strategy, contributing to several business units
including oncology, immunology, virology and genetically defined
diseases. While at Bristol-Myers Squibb, she supported the global
launches of several successful therapies in the areas of oncology,
inflammation and infectious disease, including Yervoy®, Erbitux®,
Orencia®, Sprycel®, Daklinza®, Sunvepra, Baraclude®, Atripla® and
Reyataz®. From 1995 to 2003, Dr. Heath-Chiozzi served in roles of
increasing responsibility at Abbott Laboratories, including Medical
Director, Pharmacogenetics; Senior Director, Global Marketed
Product Development and Outcomes Research; and Global Project Head,
Abbott/Millennium Obesity/Diabetes Alliance. Before joining Abbott,
she was appointed to the University of Hawaii John A. Burns School
of Medicine, where she served as Assistant Professor, and was
concurrently Director of the HIV Research Clinical at the Queen’s
Medical Center as well as Director of the Women’s Immunology
Clinical at the Kapiolani Medical Center for Women and Children, in
Honolulu. Dr. Heath-Chiozzi received her B.S. and M.D. from the
University of Utah. She received further medical training in
internal medicine at Duke University and completed fellowships in
infectious disease at Brigham & Women’s Hospital and
Dana-Farber Cancer Institute in Boston.
Yervoy®, Orencia®, Sprycel®, Daklinza®, Baraclude®, Atripla® and
Reyataz® are registered trademarks of Bristol-Myers Squibb.
Erbitux® is a registered trademark of Eli Lilly & Co.
About Celldex Therapeutics, Inc.Celldex is
developing targeted therapeutics to address devastating diseases
for which available treatments are inadequate. Our pipeline
includes antibodies, antibody-drug conjugates and other
protein-based therapeutics derived from a broad set of
complementary technologies which have the ability to engage the
human immune system and/or directly inhibit tumors to treat
specific types of cancer or other diseases. Visit
www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. These statements are typically preceded by
words such as "believes," "expects," "anticipates," "intends,"
"will," "may," "should," or similar expressions. These
forward-looking statements reflect management's current knowledge,
assumptions, judgment and expectations regarding future performance
or events. Although management believes that the expectations
reflected in such statements are reasonable, they give no assurance
that such expectations will prove to be correct or that those goals
will be achieved, and you should be aware that actual results could
differ materially from those contained in the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to successfully complete research and further development and
commercialization of glembatumumab vedotin and other Company drug
candidates; our ability to obtain additional capital to meet our
long-term liquidity needs on acceptable terms, or at all, including
the additional capital which will be necessary to complete the
clinical trials that we have initiated or plan to initiate; our
ability to realize the anticipated benefits from the acquisition of
Kolltan and to operate the combined business efficiently; the
uncertainties inherent in clinical testing and accruing patients
for clinical trials; our limited experience in bringing programs
through Phase 3 clinical trials; our ability to manage and
successfully complete multiple clinical trials and the research and
development efforts for our multiple products at varying stages of
development; the availability, cost, delivery and quality of
clinical and commercial grade materials produced by our own
manufacturing facility or supplied by contract manufacturers, who
may be our sole source of supply; the timing, cost and uncertainty
of obtaining regulatory approvals; our ability to maintain and
derive benefit from the Fast Track designation for glembatumumab
vedotin which does not change the standards for regulatory approval
or guarantee regulatory approval on an expedited basis, or at all;
the failure of the market for the Company's programs to continue to
develop; our ability to protect the Company's intellectual
property; the loss of any executive officers or key personnel or
consultants; competition; changes in the regulatory landscape or
the imposition of regulations that affect the Company's products;
and other factors listed under "Risk Factors" in our annual report
on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact
Sarah CavanaughSenior Vice President, Corporate Affairs &
AdministrationCelldex Therapeutics, Inc.(781)
433-3161scavanaugh@celldex.com
Charles LilesAssociate Director, Investor Relations & Corp
CommunicationsCelldex Therapeutics, Inc.(617)
383-3433cliles@celldex.com
Dan BudwickFounder, 1AB Media(973) 271-6085dan@1abmedia.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2023 to Apr 2024